- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Patricia Coyle: Ofatumumab Has the Benefit of Being Taken at Home
The biggest difference between ocrelizumab and the recently approved ofatumumab is that ofatumumab can be taken at home for relapsing forms of multiple sclerosis (MS), explained Patricia K. Coyle, MD.
Ofatumumab was recently approved to treat relapsing forms of multiple sclerosis (MS), making it a direct competitor of ocrelizumab; the biggest difference between the 2 therapies is that ofatumumab can be taken at home, explained Patricia K. Coyle, MD, director of the MS Comprehensive Care Center and professor of neurology at Stony Brook University Neurosciences Institute.
Transcript
Ofatumumab was recently approved for relapsing forms of multiple sclerosis. How does it fit into the treatment landscape for patients with MS?
Ofatumumab is a human anti-CD20. As an MS anti-CD20, it is a high-efficacy monoclonal agent. It will be a direct competitor for ocrelizumab, the humanized anti-CD20. Probably the biggest difference is that ofatumumab is given by a subcutaneous monthly injection every 4 weeks and can be delivered at home. This is after a 20 milligram, 3 times over 2 weeks loading dose, and then it's 20 milligrams [subcutaneously] every 4 weeks. That's in contrast to ocrelizumab, which is given intravenously every 6 months.
So, I think you have now a choice between 2 anti-CD20s that are high-efficacy, relatively safe options. One you come to an infusion center twice a year, the other you inject at home subcutaneously monthly.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Health Equity and Access Weekly Roundup: May 11, 2024
May 11th 2024This week's topics include frameworks for improving health equity nationwide, addressing social determinants of health, discussing CMS's Medicare rules, investigating breast cancer treatment refusal, and exploring HIV and major depressive disorder in underrepresented groups.
Read More
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
